166 related articles for article (PubMed ID: 23069745)
1. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands.
Leunis A; Blommestein HM; Huijgens PC; Blijlevens NM; Jongen-Lavrencic M; Uyl-de Groot CA
Leuk Res; 2013 Mar; 37(3):245-50. PubMed ID: 23069745
[TBL] [Abstract][Full Text] [Related]
2. Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.
Van de Velde AL; Beutels P; Smits EL; Van Tendeloo VF; Nijs G; Anguille S; Verlinden A; Gadisseur AP; Schroyens WA; Dom S; Cornille I; Goossens H; Berneman ZN
Leuk Res; 2016 Jul; 46():26-9. PubMed ID: 27111858
[TBL] [Abstract][Full Text] [Related]
3. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia.
van Agthoven M; Groot MT; Verdonck LF; Löwenberg B; Schattenberg AV; Oudshoorn M; Hagenbeek A; Cornelissen JJ; Uyl-de Groot CA; Willemze R
Bone Marrow Transplant; 2002 Aug; 30(4):243-51. PubMed ID: 12203141
[TBL] [Abstract][Full Text] [Related]
5. [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation].
Groot MT; van Agthoven M; Löwenberg B; Willemze R; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2004 Mar; 148(10):480-4. PubMed ID: 15042895
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of consolidation treatments for acute myeloid leukemia in high-risk pediatric patients within the Colombian healthcare system].
García M; Chicaíza LA; Quitián H; Linares A; Ramírez Ó
Biomedica; 2015; 35(4):549-56. PubMed ID: 26844444
[TBL] [Abstract][Full Text] [Related]
7. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia.
Cordonnier C; Maury S; Esperou H; Pautas C; Beaune J; Rodet M; Lagrange JL; Rouard H; Beaumont JL; Bassompierre F; Glückman E; Kuentz M; Durand-Zaleski I
Bone Marrow Transplant; 2005 Oct; 36(7):649-54. PubMed ID: 16044135
[TBL] [Abstract][Full Text] [Related]
8. Healthcare expenditures of older patients with AML are similar between HMA and intensive induction chemotherapy.
Lachowiez C; Kearney M; Meyers G; Maziarz RT; Cook RJ
Leuk Lymphoma; 2019 Nov; 60(11):2817-2820. PubMed ID: 31056994
[No Abstract] [Full Text] [Related]
9. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.
Schlenk RF; Döhner K; Mack S; Stoppel M; Király F; Götze K; Hartmann F; Horst HA; Koller E; Petzer A; Grimminger W; Kobbe G; Glasmacher A; Salwender H; Kirchen H; Haase D; Kremers S; Matzdorff A; Benner A; Döhner H
J Clin Oncol; 2010 Oct; 28(30):4642-8. PubMed ID: 20805454
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
[TBL] [Abstract][Full Text] [Related]
11. [Russian experts' clinical guidelines for acute myeloid leukemia treatment in patients less than 60 years of age].
Savchenko VG; Parovichnikova EN; Afanas'ev BV; Gritsaev SV; Semochkin SV; Bondarenko SN; Troitskaia VV; Sokolov AN; Kuz'mina LA; Kliasova GA; Baranova OIu; Lapin VA; Konstantinova TS; Samoĭlova OS; Kaporskaia TS; Shatokhin SV
Ter Arkh; 2014; 86(7):4-13. PubMed ID: 25314772
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
13. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the netherlands.
Uyl-de Groot CA; Gelderblom-den Hartog J; Huijgens PC; Willemze R; van Ineveld BM
J Hematother Stem Cell Res; 2001 Feb; 10(1):187-92. PubMed ID: 11276372
[TBL] [Abstract][Full Text] [Related]
14. [Bone marrow transplantation versus maintenance chemotherapy for adult acute leukemia in first remission].
Suzuki R; Iida H; Taji H; Murata M; Sugihara T; Minami S; Kodera Y
Rinsho Ketsueki; 1996 Dec; 37(12):1362-70. PubMed ID: 8997123
[TBL] [Abstract][Full Text] [Related]
15. [The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].
Parovichnikova EN; Kliasova GA; Sokolov AN; Troitskaia VV; Kokhno AV; Kuz'mina LA; Shaforostova II; Ryzhko VV; Kravchenko SK; Bondarenko SN; Lapin VA; Pristupa AS; Konstantinova TS; Zagoskina TP; Ialykomov IV; Moskov VI; Anchukova LV; Kaporskaia TS; Volodicheva EM; Kaplanov KD; Kondakova EV; Samoĭlova OS; Gavrilova LV; Kulikov SM; Savchenko VG
Ter Arkh; 2012; 84(7):10-5. PubMed ID: 23038965
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital.
Ngamkiatphaisan S; Sriratanaban J; Kamolratanakul P; Intragumtornchai T; Noppakun N; Jongudomsuk P
J Med Assoc Thai; 2007 Dec; 90(12):2565-73. PubMed ID: 18386705
[TBL] [Abstract][Full Text] [Related]
17. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission.
Dufoir T; Saux MC; Terraza B; Marit G; Guessard S; Foulon G; Reiffers J
Bone Marrow Transplant; 1992 Oct; 10(4):323-9. PubMed ID: 1422487
[TBL] [Abstract][Full Text] [Related]
18. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands.
Uyl-de Groot CA; Okhuijsen SY; Hagenbeek A; Huijgens PC; van Imhoff GW; Löwenberg B; Verdonck LF; Rutten FF
Bone Marrow Transplant; 1995 Apr; 15(4):605-10. PubMed ID: 7655388
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of acute myeloid leukemia: a literature review.
Redaelli A; Botteman MF; Stephens JM; Brandt S; Pashos CL
Cancer Treat Rev; 2004 May; 30(3):237-47. PubMed ID: 15059647
[TBL] [Abstract][Full Text] [Related]
20. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M
Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
